Our Vision
Fresh Wind Biotechnologies, Inc. is developing innovative and potent cellular immunotherapies to enhance cancer patient's every day experiences. Founded in 2020, our incredible team of scientists, clinicians, bioinformaticians and business development experts have worked tirelessly to bring our company to the forefront of the fight against cancer.
We dedicate our resources to develop and to commercialize highly effective and safe personalized cancer treatment. We focus on integration of high-throughput platforms, state-of-art data science and engineering, and innovative cellular therapy technologies to advance precision oncology.
Our Technology
Adoptive cell therapy (ACT) utilizes and enhances the cells of our own immune system to eliminate cancer. Naturally occurring T cells in cancer patients are often capable of targeting their cancers cells. However, they aren’t always enough to carry out their mission to eliminate tumors, due to
being lack of activity, or
being unable to maintain the activity for a sufficiently long time, or
being inadequate numbers.
We specialize in development of one form of ACT to address these issues, called tumor-infiltrating lymphocyte (TIL) therapy. Our technologies isolate patient’s own T cells that have infiltrated their tumors, activate and expand them. Then a plenty of these activated T cells are re-infused into the patients to destroy tumors. In addition, in order to further improve the efficacy and safety of treatment, we develop the technologies to enhance TILs with the abilities to target neoantigen that are specific to patient tumor cells.
Our Platforms
Our Leadership
Fuli Yu, Ph.D.
Dr. Yu founded Fresh Wind Biotechnologies and has served as our Chief Executive Officer since 2020. Prior to Fresh Wind, he worked as Chief Information Officer at Berry Genomics from 2015 to 2020, where he built the entire IT/Informatics team from tens of FTEs to >200 FTEs. He was also an assistant professor at Baylor College of Medicine from 2008 to 2020, substantially contributing in the international genomics consortia, particularly HapMap3, the 1000 Genomes Project, and CHARGE. Previously, he was a postdoctoral researcher at Harvard Medical School and Broad Institute from 2005 to 2008. He received a Ph.D. in Genomics and Genetics from Baylor College of Medicine and a B.S. in Molecular Biology from Nankai University.
"A biomedical researcher, an innovator and team builder, a biotech entrepreneur, and a person with aspiration, I am thrilled to be part of this revolutionary phase in precision medicine. As innovations from various disciplines converge rapidly, it is becoming possible to challenge the once impossible, more than ever before! Our team in Fresh Wind brings together our years of experiences, aiming to seamlessly integrate multi-omics discovery into cellular therapeutic development. We might come from different geographic areas, with diverse life backgrounds, nevertheless, we share ONE vision in Fresh Wind: translate technologies into meaningful clinical actions, to SAVE and CURE!"
Tianhong Xu, M.D., Ph.D.
Dr. Xu co-founded Fresh Wind Biotechnologies and has served as our Chief Strategic Officer since 2020. He is also a founding partner at Virtus Inspire (VI) Ventures since 2015. Prior to that, he worked as a partner at WI Harper Group from 2013 to 2015 and Vangoo Capitol from 2011 to 2013, focusing on investments in the medical device, biotech, and healthcare service. Previously, he was a medical industry expert at the United Nations-Industrial Development Organization (UNIDO) from 2009 to 2011, where he directed the upgrade of medical industrial clusters in China through investment promotion, technology transfer, and management consulting. Formerly, he was a clinical doctor at Renji Hospital in China. He received a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine, and a M.D. from Fudan University.
“I am a doctor, researcher and investor. Above all, I am bounded to bring disruptive know-hows to the market place for maximizing socioeconomic benefits. Fresh Wind Biotech is the right formula for reaching this objective.”